FDA approves ViiV's two-drug HIV regimen

FDA approved Viiv's Dovato dolutegravir/lamivudine for HIV-1 infection in treatment-naïve adults. The product is a once-daily, single-tablet regimen of dolutegravir and lamivudine that the company plans to launch in 2-3 weeks at a wholesale acquisition cost (WAC) of $2,295 per month.

Gilead Sciences Inc. (NASDAQ:GILD) markets three-drug regimen Biktarvy bictegravir/emtricitabine/tenofovir alafenamide to treat HIV-1 infection. Biktarvy's WAC for a 30-day supply of the drug is $3,090...